Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Moehler, Markus ^a   Gepfner Tuma, Irina ^a   Maderer, Annett ^a   Thuss Patience, Peter C ^b   Ruessel, Joern ^c   Hegewisch Becker, Susanna ^d   Wilke, Hansjochen ^e   Al Batran, Salah Eddin ^f   Rafiyan, Mohammad Reza ^f   Weißinger, Florian ^g   Schmoll, Hans Joachim ^c   Kullmann, Frank ^h   von Weikersthal, Ludwig Fischer ⁱ   Siveke, Jens T ^j   Weusmann, Jens ^a   Kanzler, Stephan ^k   Schimanski, Carl Christoph ^l   Otte, Melanie ^m   Schollenberger, Lukas ⁿ   Koenig, Jochem ^o   Galle, Peter R ^a   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d Hamatologisch Onkologische Praxis   (Germany)

^e KLINIKEN ESSEN MITTE   (Germany)

^f KRANKENHAUS NORDWEST   (Germany)

^g EVANGELISCHES KRANKENHAUS   (Germany)

^h Klinikum Weiden   (Germany)

ⁱ Gesundheitszentrum St Marien GmbH   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k Leopoldina Krankenhaus   (Germany)

^l Marienkrankenhaus Darmstadt   (Germany)

^m Praxisgemeinschaft für Onkologie und Urologie   (Germany)

ⁿ Interdisciplinary Centre for Clinical Trials   (Germany)

^o UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

Chemorefractory advanced gastric cancer; FOLFIRI; Sunitinib; Tyrosine kinase inhibitor; VEGF

Indexed keywords

ACID PHOSPHATASE; BILIRUBIN; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; PLACEBO; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; SURVIVAL TIME; TREATMENT DURATION; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; STOMACH NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PYRROLES; STOMACH NEOPLASMS;

EID: 84984674762     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2736-9     Document Type: Article

References (47)

1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
2. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. The Cochrane database of systematic reviews. 2010;3, CD004064.
3. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490-9.
4. Pasini F, Fraccon AP, Dem G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011;31(10):3543-54.
5. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10 Suppl 3:49-58.
6. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306-14.
7. Kang JH, Lee SI, Limdo H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513-8.
8. Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, et al. Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy? World journal of gastroenterology : WJG. 2007;13(26):3605-9.
9. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858-63.
10. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2(10):1679-84.
11. Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, Schmidt T, Ott K. Angiogenic and growth factors in gastric cancer. J Surg Res. 2015;194(2):420-9.
12. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119-27.
13. de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N, Escudier B, Van Cutsem E, Carmeliet P, Scherer SJ, et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis. 2014;17(4):909-20.
14. Park do J, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, Suh YS, Lee HS, Yang HK, Kim HH, et al. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:1508-15.
15. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002;236(1):37-42.
16. Park do J, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, Suh YS, Lee HS, Yang HK, Kim HH, et al. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S1508-15.
17. Moehler M, Schwarz S, Wagner AD. Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy. Curr Cancer Drug Targets. 2011;11(6):681-7.
18. Dimberg J, Hugander A, Lofgren S, Wagsater D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 2007;19(1):11-5.
19. Arbab AS. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol. 2012;27(5):549-57.
20. Fei F, Stoddart S, Muschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 2010;24(4):813-20.
21. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol. 2004;14(3):195-200.
22. Balkwill F. Chemokine biology in cancer. Semin Immunol. 2003;15(1):49-55.
23. Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol. 1998;10(3):179-85.
24. Ying J, Xu Q, Zhang G, Liu B, Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Medical oncology (Northwood, London, England). 2012;29(3):1716-22.
25. Wang X, Zhang H, He H, Shen Z, Tang Z, Xu J, Sun Y. Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection. Cancer Sci. 2014;105(11):1447-56.
26. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597-605.
27. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(7):884-96.
28. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. European journal of cancer (Oxford, England : 1990). 2011;47(10):1511-20.
29. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29(6):1449-58.
30. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011;22(6):1358-66.
31. Cook N, Marshall A, Blazeby JM, Bridgewater JA, Wadsley J, Coxon FY. Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. J Clin Oncol. 2013;31:2013. ASCO 2013. Chicago.
32. Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers. 2013;5(1):64-91.
33. Ferry DR, Dutton S, Mansoor W. Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib). Vienna: ESMO; 2012.
34. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-9.
35. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-35.
36. Starling N, Vazquez-Mazon F, Cunningham D, Chau I, Tabernero J, Ramos FJ, Iveson TJ, Saunders MP, Aranda E, Countouriotis AM, et al. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol. 2012;23(1):119-27.
37. Jeon EK, Hong SH, Kim TH, Jung SE, Park JC, Won HS, Ko YH, Rho SY, Hong YS. Modified FOLFIRI as second-line chemotherapy after failure of modified FOLFOX-4 in advanced gastric cancer. Cancer Res Treat. 2011;43(3):148-53.
38. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol. 2007;37(10):744-9.
39. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, Bondarenko I, Jonker DJ, Sun Y, De la Cruz JA, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(10):1341-7.
40. Park SH, Lee WK, Chung M, Bang SM, Cho EK, Lee JH, Shin DB. Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol. 2006;57(3):289-94.
41. Mross K. Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology. Pharm Unserer Zeit. 2008;37(5):404-15.
42. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol. 2000;17(1):149-52.
43. Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sorgel F, Jaehde U, Burkholder I, Moritz B, Buchert M. FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. Int J Clin Pharmacol Ther. 2014;52(8):642-52.
44. Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. European journal of cancer (Oxford, England : 1990). 2014;50(18):3125-35.
45. Brossa A, Grange C, Mancuso L, Annaratone L, Satolli MA, Mazzone M, Camussi G, Bussolati B. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Oncotarget. 2015;6(13):11295-309.
46. Norton KA, Han Z, Popel AS, Pandey NB. Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells. OncoTargets and therapy. 2014;7:1571-82.
47. Collet G, Lamerant-Fayel N, Tertil M, El Hafny-Rahbi B, Stepniewski J, Guichard A, Foucault-Collet A, Klimkiewicz K, Petoud S, Matejuk A, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther. 2014;13(1):165-78.